201. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
- Author
-
Congly SE, Shaheen AA, and Swain MG
- Subjects
- Adult, Aged, Alberta epidemiology, Cohort Studies, Community Health Services organization & administration, Computer Simulation, Cost-Benefit Analysis, Decision Making, Organizational, Female, Humans, Liver diagnostic imaging, Liver pathology, Liver Cirrhosis economics, Liver Cirrhosis etiology, Liver Cirrhosis prevention & control, Male, Middle Aged, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease economics, Non-alcoholic Fatty Liver Disease pathology, Risk Assessment economics, Risk Assessment methods, Severity of Illness Index, Community Health Services economics, Elasticity Imaging Techniques economics, Liver Cirrhosis epidemiology, Models, Economic, Non-alcoholic Fatty Liver Disease diagnosis
- Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent worldwide. Identifying high-risk patients is critical to best utilize limited health care resources. We established a community-based care pathway using 2D ultrasound shear wave elastography (SWE) to identify high risk patients with NAFLD. Our objective was to assess the cost-effectiveness of various non-invasive strategies to correctly identify high-risk patients., Methods: A decision-analytic model was created using a payer's perspective for a hypothetical patient with NAFLD. FIB-4 [≥1.3], NAFLD fibrosis score (NFS) [≥-1.455], SWE [≥8 kPa], transient elastography (TE) [≥8 kPa], and sequential strategies with FIB-4 or NFS followed by either SWE or TE were compared to identify patients with either significant (≥F2) or advanced fibrosis (≥F3). Model inputs were obtained from local data and published literature. The cost/correct diagnosis of advanced NAFLD was obtained and univariate sensitivity analysis was performed., Results: For ≥F2 fibrosis, FIB-4/SWE cost $148.75/correct diagnosis while SWE cost $276.42/correct diagnosis, identifying 84% of patients correctly. For ≥F3 fibrosis, using FIB-4/SWE correctly identified 92% of diagnoses and dominated all other strategies. The ranking of strategies was unchanged when stratified by normal or abnormal ALT. For ≥F3 fibrosis, the cost/correct diagnosis was less in the normal ALT group., Conclusions: SWE based strategies were the most cost effective for diagnosing ≥F2 fibrosis. For ≥F3 fibrosis, FIB-4 followed by SWE was the most effective and least costly strategy. Further evaluation of the timing of repeating non-invasive strategies are required to enhance the cost-effective management of NAFLD., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: SEC reports clinical trial support from Gilead Sciences, Genfit, Boehringer Ingelheim, Allergan, BMS and Sequana and has provided consulting services for Intercept Pharmaceuticals, Eisai, and AstraZeneca and Paladin Labs outside the submitted work. AAS reports research grant support from grants from Gilead Sciences and Intercept Pharmaceuticals and has provided consulting services for Intercept Pharmaceuticals and Gilead Sciences outside the submitted work. MGS reports consulting or speaker services for Intercept Pharmaceuticals, Gilead Sciences, Abbott, Novartis and research and clinical trial support from Gilead Sciences, Intercept, CymaBay, Genkyotex, Novartis, Pfizer, Genfit, GSK, Astra Zeneca outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2021
- Full Text
- View/download PDF